Physician profile
John Albert Rhoades
NPI 1396267373
$1,936.16
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $397 · 2023: $1,442 · 2024: $96.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.21 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $247.36 | 2022-2023 | Verquvo |
| Amgen INC. | $219.14 | 2023 | Repatha |
| Pfizer INC. | $188.21 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $157.96 | 2022-2023 | Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $152.20 | 2023 | Xarelto |
| Abbott Laboratories | $149.27 | 2023-2024 | Amplatzer Amulet |
| Sanofi-Aventis U.S. LLC | $126.68 | 2022-2023 | |
| Esperion Therapeutics, INC. | $112.67 | 2022-2023 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $101.03 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $89.50 | 2022-2023 | Livalo |
| Novartis Pharmaceuticals Corporation | $88.34 | 2022-2023 | |
| Novo Nordisk INC | $78.98 | 2022-2023 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $57.85 | 2023 | Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $44.71 | 2022-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $30.97 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.91 | 2022-2023 | Mounjaro |
| Medtronic, INC. | $21.57 | 2023 | Reveal Linq |
| Cvrx, INC. | $21.13 | 2023 | Barostim Neo System |
| Abiomed | $20.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rhoades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.